Skip to Content

AnaSed (20 mg/mL) (Canada)

This page contains information on AnaSed (20 mg/mL) for veterinary use.
The information provided typically includes the following:
  • AnaSed (20 mg/mL) Indications
  • Warnings and cautions for AnaSed (20 mg/mL)
  • Direction and dosage information for AnaSed (20 mg/mL)

AnaSed (20 mg/mL)

This treatment applies to the following species:
Manufacturer: Veterinary Healthcare Solutions

DIN 02094908

Sterile

Net Contents: 20 mL

Veterinary Use Only

Xylazine Injection 20 mg/mL

(as xylazine hydrochloride)

Analgesic and Sedative For Use in Dogs

Description

Anased® is supplied as a sterile solution.

Each mL contains: medicinal ingredient xylazine hydrochloride equivalent to 20 mg, and the following non-medicinal ingredients: methylparaben 0.9 mg, propylparaben 0.1 mg, sodium citrate dihydrate 5.0 mg and water for injection. The pH is adjusted with hydrochloric acid.

Pharmacology

Xylazine, a non-narcotic compound, is an analgesic and sedative as well as a muscle relaxant. Its analgesic and sedative activity is related to central nervous system depression. Its muscle relaxant effect is based on inhibition of the intraneural transmission of impulses in the central nervous system. The principal pharmacological activities develop within 10 to 15 minutes after intramuscular or subcutaneous injection, and within three to five minutes following intravenous administration.

A sleeplike state, the depth of which is dose-dependent, is usually maintained for one to two hours, while analgesia lasts from 15 to 30 minutes. The centrally-acting muscle relaxant effect causes relaxation of the skeletal musculature complementing sedation and analgesia.

In animals under the influence of AnaSed, the respiratory rate is reduced as in natural sleep. Following treatment with AnaSed, the heart rate is decreased and a transient change in the conductivity of the cardiac muscle may occur, as evidenced by a partial atrioventricular block. This resembles the atrioventricular block often observed in normal animals. Intravenous administration of AnaSed causes a transient rise in blood pressure, followed by a slight decrease.

AnaSed has no effect on blood clotting time or other hematological parameters.

AnaSed (20 mg/mL) Indications

AnaSed should be used in dogs when it is desirable to produce a state of sedation accompanied by a shorter period of analgesia. It has been used successfully as follows:

1. Diagnostic procedures - oral and ophthalmic examinations, abdominal palpation, rectal palpation, vaginal examination, catheterization of the bladder and radiographic examinations of head and extremities.

2. Orthopedic procedures, such as the application of casting materials and splints.

3. Dental procedures.

4. Minor surgical procedures of short duration such as debridement, removal of cutaneous neoplasms and suturing of lacerations.

5. To calm and facilitate the handling of fractious animals.

6. Therapeutic medication for sedation and relief of pain following injury or surgery.

7. Major surgical procedures:

a. When used as a preanesthetic to general anesthesia.

b. When used in conjunction with local anesthetics.

Contraindications

Doses in excess of those recommended should not be given. While xylazine is tolerated in dogs at 4 times the recommended dose, doses of this magnitude produce muscle tremors, emesis and long periods of sedation.

Do not use AnaSed in conjunction with tranquilizers.

Dosage and Administration

1. Dosage:

Intravenous - 0.5 mL/9 kg of body weight or 1.1 mg/kg.

Intramuscular or Subcutaneous - 1.0 mL/9 kg of body weight or 2.2 mg/kg.

Since vomiting may occur (see SIDE EFFECTS), fasting for 6-24 hours prior to the use of AnaSed may reduce the incidence; the I.V. route results in the least vomiting.

Following the injection of AnaSed, the animal should be allowed to rest quietly until the full effect has been reached.

These dosages produce sedation which is usually maintained for 1 to 2 hours and analgesia which lasts for 15 to 30 minutes.

2. Preanesthetic to Local Anesthesia
AnaSed at the recommended dosages can be used in conjunction with local anesthetics, such as procaine or lidocaine.

3. Preanesthetic to General Anesthesia
AnaSed at the recommended dosage rates produces an additive effect to central nervous system depressants such as pentobarbital sodium, thiopental sodium and thiamylal sodium. Therefore, the dosage of such compounds should be reduced and administered to the desired effect. In general, only one-third (1/3) to one-half (1/2) of the calculated dosage of the barbiturates will be needed to produce a surgical plane of anesthesia.

Postanesthetic or emergence excitement has not been observed in animals pre-anesthetized with AnaSed.

AnaSed has been used successfully as a preanesthetic agent for pentobarbital sodium, thiopental sodium, thiamylal sodium, nitrous oxide, ether, halothane and methoxyflurane anesthesia.

Side Effects

Emesis occurs occasionally in dogs soon after the administration of xylazine, but before clinical sedation is evident. When observed, emesis usually occurs only a single time, after which there is no further emetic effect. The use of antiemetics may delay this phenomenon. The occurrence of emesis may be considered a desirable effect when xylazine is administered as a preanesthetic to general anesthesia.

Xylazine used at the recommended dosage levels may occasionally cause slight muscle tremors, bradycardia with partial A-V heart block and a reduced respiratory rate. Should excessive respiratory depression occur following the use of AnaSed (xylazine), administer Yobine® (yohimbine 2 mg/mL) DIN 00769959, and provide artificial respiration.

Gaseous distension of the stomach may occur in dogs treated with xylazine making radiographic interpretation more difficult.

Movement in response to sharp auditory stimuli may be observed.

Precautions

Clinical results with xylazine have not revealed any detrimental effects when the compound is administered to pregnant dogs. However, until more definitive studies are completed, xylazine is not recommended for use in these animals.

Careful consideration should be given before administering the product to dogs with significantly depressed respiration, severe pathologic heart disease, advanced liver or kidney disease, severe endotoxic or traumatic shock and stress conditions such as extreme heat, cold or fatigue.

Since an additive effect results from the use of xylazine and the barbiturate compounds, it should be used with caution with these central nervous system depressants. Products known to produce respiratory depression or apnea, such as thiamylal sodium, should be given at a reduced dosage and, when injected intravenously, should be administered slowly. When intravenous administration is desired, avoid perivascular injection in order to achieve the desired effect.

Bradycardia and an arrhythmia in the form of incomplete atrioventricular block have been reported following xylazine administration. Although clinically the importance of this effect is questioned, a standard dose of atropine given prior to or following xylazine will greatly decrease the incidence.

The analgesic effect is variable, and depth should be carefully assayed prior to surgical/clinical procedures. In spite of sedation, the practitioner and handlers should proceed with caution since defense reactions may not be diminished.

While sedation usually lasts from 1 to 2 hours, recovery periods in excess of 4 to 5 hours have been reported in dogs.

References

1. Upson, DW. Upson’s handbook of clinical veterinary pharmacology. Bonner Springs, KS: VM Publishing, Inc, 1981; 148, 248.

2. Detweiler DK. The diagnosis and significance of cardiac arrhythmias. In: Catcott EJ, Smithcors JF, eds. Progress in equine practice. Wheaton, IL: American Veterinary Publications, Inc, 1966; 280-281.

3. Bargai U: The effect of xylazine hydrochloride on the radiographic appearance of the stomach and intestine in the dog. Vet Radiol 1982;23:60-63.

4. VET-A-MIX, a division of LLOYD, Inc, Research.

Manufactured by: LLOYD, Inc. of Iowa, Shenandoah, Iowa 51601 U.S.A.

Manufactured for: Veterinary Healthcare Solutions, 2525 Tecumseh Road West, Windsor, ON, Canada N9B 1W4

Rev1111

NAC No.: 16560010

VETERINARY HEALTHCARE SOLUTIONS, INC.
2525 TECUMSEH ROAD WEST, WINDSOR, ON, N9B 1W4
Telephone:   519-790-9561
Fax:   1-866-651-9959
Website:   www.vhsvets.com
Every effort has been made to ensure the accuracy of the AnaSed (20 mg/mL) information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.

Copyright © 2016 North American Compendiums. Updated: 2016-08-21

Hide